According to @StockMKTNewz, Novo Nordisk (NVO) executive Mike Doustdar said up to 1.5 million patients in the United States could be using compounded versions of GLP-1 weight-loss drugs, citing Seeking Alpha as the source. Source: @StockMKTNewz; Seeking Alpha. For traders, this figure quantifies a sizable parallel channel outside branded supply that can shape headline sensitivity and liquidity in NVO and GLP-1 names when related updates cross the tape. Source: @StockMKTNewz. Crypto participants monitoring cross-asset risk may watch for any risk-sentiment spillover from large-cap healthcare headlines as this item circulates across market feeds today. Source: @StockMKTNewz.